Prognostic impact of MALs and potential immunotherapy targets in uveal melanoma

Jing Yang; Zhou Fu; Qin Xiang

doi:10.1002/pdi3.54

Pediatric Discovery ›› 2024, Vol. 2 ›› Issue (3) : e54 DOI: 10.1002/pdi3.54

RESEARCH ARTICLE

Prognostic impact of MALs and potential immunotherapy targets in uveal melanoma

Jing Yang ¹^,²
, Zhou Fu ¹^,²
, Qin Xiang ¹^,²^,^†

Author information +

History +

PDF

Abstract

Uveal melanoma (UM) is the most common primary ocular malignancy in adults, and the 5-year disease-related mortality rate is 30%. MAL proteolipid family (MALs), including T-cell differentiation protein (MAL), T-cell differentiation protein 2 (MAL2), and T-cell differentiation protein like (MALL), were involved in the progression and prognosis of many different cancers. However, the role of MALs in UM was not reported. UM samples were extracted from The Cancer Genome Atlas. R software (R3.6.3) was used to comprehensively analyze the roles of the MALs (signiﬁcance threshold: p < 0.05). MALs mRNA expression was changed in UM tissues. In terms of tumor stage, MAL2 was highly expressed in T4 (p = 0.021). The ROC curves indicated that MAL2 and MALL were prognostic biomarkers for 1- and 3-year survival in UM patients, and MAL2 also could predict 5-year survival for UM patients. Then, the univariable and multivariable analysis showed that MAL2 and MALL were independent prognostic biomarkers. Next, we assessed the immune microenvironment of MALs in UM. MAL had no correlation with B7-H3, but MAL2 and MALL had a positive correlation with B7-H3. Our results revealed that the MAL proteolipid family may be prognostic biomarkers for UM patients and that B7-H3 may be a novel immunotherapy target for UM.

Keywords

immunotherapy target / MAL proteolipid family / prognosis biomarker / uveal melanoma

Cite this article

Download citation ▾

Jing Yang, Zhou Fu, Qin Xiang. Prognostic impact of MALs and potential immunotherapy targets in uveal melanoma. Pediatric Discovery, 2024, 2(3): e54 DOI:10.1002/pdi3.54

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	KarlssonJ, Nilsson LM, MitraS, et al. Molecular profiling of driver events in metastatic uveal melanoma. Nat Commun. 2020;11(1):1894.

[2]	DuranteMA, Rodriguez DA, KurtenbachS, et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat Commun. 2020;11(1):496.

[3]	SinghAD, TurellME, TophamAK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881-1885.

[4]	JagerMJ, Shields CL, CebullaCM, et al. Uveal melanoma. Nat Rev Dis Prim. 2020;6(1):24.

[5]	MeiS, LiY, KangX. Prognostic and functional analysis of NPY6R in uveal melanoma using bioinformatics. Dis Markers. 2022;2022:4143447-4143514.

[6]	RobertsonAG, ShihJ, YauC, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2018;33(1):151.

[7]	LiD, ZhangJ, WuL, YangX, ChenZ, Yuan J. Myelin and lymphocyte protein (MAL):a novel biomarker for uterine corpus endometrial carcinoma. Cancer Manag Res. 2021;13:7311-7323.

[8]	FangY, WangL, WanC, et al. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest. 2021;131(1):e140837.

[9]	FanJ, YanD, TengM, et al. Digital transcript profile analysis with aRNA-LongSAGE validates FERMT1 as a potential novel prognostic marker for colon cancer. Clin Cancer Res. 2011;17(9):2908-2918.

[10]	Rubio-RamosA, Labat-De-Hoz L, CorreasI, AlonsoMA. The MAL protein, an integral component of specialized membranes, in normal cells and cancer. Cells. 2021;10(5):1065.

[11]	VivianJ, RaoAA, NothaftFA, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314-316.

[12]	FifeD. Flexplot: graphically-based data analysis. Psychol Methods. 2021;27(4):477-496.

[13]	LiuJ, Lichtenberg T, HoadleyKA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400-416.e11.

[14]	BindeaG, Mlecnik B, TosoliniM, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782-795.

[15]	HanzelmannS, Castelo R, GuinneyJ. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14(1):7.

[16]	StraatsmaBR, Diener-West M, CaldwellR, EngstromRE, Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. Indian J Ophthalmol. 2018;66(10):1395-1400.

[17]	ShengX, LiS, ChiZ, et al. Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients. Br J Ophthalmol. 2015;99(7):990-996.

[18]	ChangAE, Karnell LH, MenckHR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664-1678.

[19]	LiuJ, LuJ, LiW. A comprehensive prognostic and immunological analysis of a six-gene signature associated with glycolysis and immune response in uveal melanoma. Front Immunol. 2021;12:738068.

[20]	ShiX, XiaS, ChuY, et al. CARD11 is a prognostic biomarker and correlated with immune infiltrates in uveal melanoma. PLoS One. 2021;16(8):e0255293.